$8.04
3.00% today
Nasdaq, Feb 05, 04:21 pm CET
ISIN
US1374041093
Symbol
CADL

Candel Therapeutics Inc Stock price

$7.81
-0.89 10.23% 1M
+2.72 53.44% 6M
-0.87 10.02% YTD
+6.49 491.67% 1Y
+3.65 87.74% 3Y
+0.81 11.57% 5Y
+0.81 11.57% 10Y
Nasdaq, Closing price Tue, Feb 04 2025
+0.66 9.23%
ISIN
US1374041093
Symbol
CADL
Sector
Industry

Key metrics

Market capitalization $347.35m
Enterprise Value $346.81m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth -100.00%
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-35.55m
Free Cash Flow (TTM) Free Cash Flow $-28.69m
Cash position $16.56m
EPS (TTM) EPS $-1.74
Short interest 8.06%
Show more

Is Candel Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,821 stocks worldwide.

Candel Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Candel Therapeutics Inc:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Candel Therapeutics Inc:

Buy
100%

Financial data from Candel Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 1.06 1.06
9% 9%
-
-1.06 -1.06
6% 6%
-
- Selling and Administrative Expenses 13 13
1% 1%
-
- Research and Development Expense 21 21
1% 1%
-
-34 -34
1% 1%
-
- Depreciation and Amortization 1.06 1.06
9% 9%
-
EBIT (Operating Income) EBIT -36 -36
1% 1%
-
Net Profit -52 -52
63% 63%
-

In millions USD.

Don't miss a Thing! We will send you all news about Candel Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Candel Therapeutics Inc Stock News

Positive
Proactive Investors
23 days ago
Candel Therapeutics Inc (NASDAQ:CADL) has provided a corporate update, highlighting anticipated milestones for this year building upon significant achievements in 2024.   Updated overall survival data from phase 2a trials of its lead candidate CAN-2409 in pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC) are expected in the first quarter of 2025.
Neutral
GlobeNewsWire
23 days ago
NEEDHAM, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today highlighted recent successes across the Company's viral immunotherapy portfolio and provided an update on the Company's cash position and upc...
Positive
Seeking Alpha
about one month ago
Taking a look at the 20 best-performing stocks in 2024 of current Russell 3,000 members.
More Candel Therapeutics Inc News

Company Profile

Candel Therapeutics, Inc. operates as a biopharmaceutical company that develops and commercializes cancer immunotherapy drugs. It offers aglatimagene besadenovec (CAN-2409), a replication-deficient adenovirus that delivers within infected cancer cells the herpes simplex virus thymidine kinase (HSV-tk) gene. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Head office United States
CEO Paul-Peter Tak
Employees 42
Founded 2002
Website www.candeltx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today